Latest news with #sequencing
Yahoo
10 hours ago
- Business
- Yahoo
Ultima Genomics Selected to Support the World's Largest Proteomics Studies to Date Led by Regeneron Genetics Center
FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform has been selected to support Regeneron Genetics Center® (RGC™) and its recently launched U.S. large-scale proteomics study. The study, comprised of 200,000 blood serum samples secured by RGC from its long-standing research collaboration with Geisinger Health System, will be combined with the recently announced UK Biobank Pharma Proteomics Project, the largest proteomics study undertaken to date, which will also utilize Ultima's UG 100 sequencing platform for the analysis of 600,000 samples from UK consented participants. Combined, these studies reflect the growing role of high-throughput, cost-efficient sequencing in enabling large-scale counting applications across proteomics and other emerging omics fields. For these efforts, RGC will utilize the Olink Explore HT platform and Ultima's UG 100 platform. Ultima's technology was selected for its scalability, efficiency, and suitability for large population-level studies requiring high-throughput data generation. "We are pleased to continue supporting the ever-expanding large-scale proteomics studies that have the potential to drive important scientific and clinical insights," said Gilad Almogy, founder and CEO of Ultima Genomics. "These RGC proteomics studies build on the growing momentum we are seeing for population-scale proteomics and counting applications powered by Ultima's sequencing platform." About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit Ultima Media ContactVikki Herrera408-206-7009vikki@ View original content to download multimedia: SOURCE Ultima Genomics
Yahoo
4 days ago
- Business
- Yahoo
Canaccord Raises Price Target Of Illumina, Inc. (ILMN).
Illumina, Inc. (NASDAQ:ILMN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Kyle Mikson, an analyst at Canaccord Genuity, increased his price objective for Illumina, Inc. (NASDAQ:ILMN) shares from $87 to $99 on June 11 while keeping his rating at Hold. A research facility with medical professionals surrounded by diagnostic equipment. The announcement comes after Illumina, Inc. (NASDAQ:ILMN) CEO Jacob Thaysen stated in a podcast that when pricing pressures lessen, revenue improvements may be driven by robust volume growth from clinical customers. Thaysen stated that its long-term development plan is still in place, provided that the NovaSeq X sequencing system is adopted more widely. Canaccord is still on the sidelines even if there are indications that its performance will improve in the medium term. The recent performance of Illumina, Inc. (NASDAQ:ILMN), a significant participant in sequencing and genomics technology, has been hampered by pricing challenges. CEO Jacob Thaysen highlighted the need for clinical volume increase in promoting both future revenue growth and recovery. The implementation of the NovaSeq X platform will be essential to carrying out Illumina, Inc. (NASDAQ:ILMN)'s expansion goal. Canaccord's raised target reflects cautious optimism about improving execution while remaining neutral overall. While we acknowledge the potential of ILMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
MGI Tech Partners with Asia Pathogen Genomics Initiative to Advance Pathogen Genomics for Public Health in Asia
SINGAPORE, June 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and Asia Pathogen Genomics Initiative ("Asia PGI"), part of the Duke-NUS Centre for Outbreak Preparedness (COP), have recently announced collaboration aimed at enhancing pathogen genomics sequencing efforts across Asia. This collaboration underscores a shared commitment to supporting public health initiatives through advanced life science technology. As part of this collaboration, MGI and Asia PGI will jointly democratize the pathogen genomics sequencing technology in Singapore and across Asia. The collaborative efforts will include hosting webinars to provide practical knowledge in pathogen genomics sequencing and delivering hands-on technical training to institutions and laboratories aimed at improving capacity development in pathogen detection. In addition, MGI also announced the launch of the MGI APAC Pandemic Preparedness Program (PPP) to strengthen the capabilities of genomics institutions and laboratories in pathogen surveillance. In collaboration with Asia PGI, the PPP aims to broaden the scope of pathogen surveillance solutions available to partner countries. The program offers a differentiated and sustainable alternative, focusing on application-centric and workflow-driven solutions. For example, it supports the development of equitable, effective, relevant, and validated workflow solutions to address acute infectious diseases. "At the Duke-NUS Centre for Outbreak Preparedness, we believe that equitable access to pathogen genomic sequencing is fundamental to strengthening health security across South and Southeast Asia," said Paul Pronyk, Director of COP. "By collaborating with industry partners such as MGI, we are committed to ensuring that all communities in our region benefit from the latest advances in pathogen genomics – enabling early detection, informed response and ultimately, a healthier future for all." "We are proud to partner with Asia PGI to accelerate the application of cutting-edge sequencing technology in pathogen genomics," said Roy Tan, General Manager of MGI Asia Pacific. "Pathogen control is a pressing challenge for many countries in Asia. This partnership aims to improve the accessibility of pathogen genomics, empowering researchers and public health professionals in their fight against infectious diseases." In response to the growing demand for rapid and precise detection of infectious diseases, MGI has developed a diverse array of comprehensive products for various applications, including metagenomic sequencing, targeted sequencing, and whole genome sequencing of pathogenic microorganisms. Looking ahead, MGI is committed to continuing its innovation, providing automated, convenient, and efficient core tools for pathogen identification, drug resistance analysis, and traceability. For more information of PPP, please visit: About the Duke-NUS Centre for Outbreak Preparedness (COP) and its Asia Pathogen Genomic Initiative (Asia PGI) The Duke-NUS Centre for Outbreak Preparedness (COP) was established in 2022 to address the growing need for enhanced preparedness and response to infectious disease outbreaks in the Asian region. With a mission to bridge the gap between research, training, policy and practice, COP aims to enhance regional health security across South and Southeast Asia. The Asia Pathogen Genomic Initiative (Asia PGI) is a flagship initiative of COP, aiming to harness scientific and technical partnerships across Singapore and Asia to advance genomic sequencing for infectious disease elimination. For more information, please visit About Duke-NUS Medical School Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and 10 centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. For more information, please visit the MGI website or connect with us on Twitter, LinkedIn or YouTube. View original content to download multimedia: SOURCE MGI Tech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping
The global metagenomics market is set to reach $6.71 billion by 2031, growing at a CAGR of 15.6%. Key growth drivers include declining sequencing costs, increasing agricultural genomics focus, F&B industry expansion, and genome mapping initiatives. Challenges include high instrument costs, regulatory issues, and a shortage of skilled professionals. Notable players are Illumina, Thermo Fisher, and Roche. The consumables segment will see the highest CAGR at 16.3%, while 16S sequencing will hold a 39.5% market share by 2024. North America is expected to register the highest growth, driven by advancements in sequencing technology. Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Metagenomics Market Size, Share, Forecast & Trends Analysis by Offering (Consumable, Instruments, Software), Technology (16S, Shotgun, Whole Genome Sequencing Microbial Sequencing), Application (Environmental, Clinical, Drug Discovery) - Global Forecast to 2031" has been added to offering. The global metagenomics market is projected to reach $6.71 billion by 2031, growing at a CAGR of 15.6% from 2024 to 2031. Comprehensive research and analysis identify key drivers such as decreasing sequencing costs, growing agricultural genomics focus, food and beverage industry expansion, and increasing genome mapping initiatives. Despite these drivers, market growth is challenged by high instrument costs, regulatory concerns, and standardization issues. Opportunities for growth are presented by the rising adoption of bioinformatics and genomic data management solutions, alongside government-backed large-scale genomic sequencing projects. However, data storage and interpretation challenges, as well as a shortage of skilled professionals, pose significant hurdles. In-depth competition analysis reveals strategic movements and product portfolio assessments of leading market players, including Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pacific Biosciences of California Inc. (U.S.), and others. The consumables segment is expected to achieve the highest growth rate, a CAGR of 16.3%, due to their recurring necessity in microbial gene profiling applications. Among the technologies, the 16S sequencing segment is anticipated to dominate with a 39.5% market share in 2024, driven by the growing need to understand microbiomes and discover new bioactive compounds. Additionally, the environmental application segment will command the largest share of 26.6%, fueled by industrial and urban pollution concerns creating demand for metagenomic solutions in environmental research. Geographically, North America will register the highest growth at a CAGR of 16.9%, spurred by a focus on personalized medicine development and microbial genomics research. Technological advancements in sequencing and decreasing costs further bolster the metagenomics market in the region. Scope of the Report:Metagenomics Market Assessment - by Offering Consumables Instruments Software & Services Sequencing & Data Analysis Services Metagenomics Market Assessment - by Technology 16S Sequencing Shotgun Metagenomic Sequencing Whole Genome Sequencing Other Technologies (Note: Other technologies include targeted microbial sequencing, meta transcriptome sequencing, and pyrosequencing.) Metagenomics Market Assessment - by Application Environmental Applications Clinical Diagnostics Drug Discovery Biotechnology Other Applications (Note: Other applications include food & nutrition, agriculture & soil health, marine microbiomes, and extremophiles.) Metagenomics Market Assessment - by Geography North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe (RoE) Asia-Pacific (APAC) China Japan India Australia Rest of Asia-Pacific (RoAPAC) Latin America Middle East & Africa Key Topics Covered: 1. Market Definition & Scope 2. Research Methodology 3. Executive Summary 4. Factors Affecting Market Growth 5. Metagenomics Market Assessment-By Offering 6. Metagenomics Market Assessment-By Technology 7. Metagenomics Market Assessment-By Application 8. Metagenomics Market Assessment-By Geography 9. Competition Analysis 10. Company Profiles Illumina Inc. (U.S.) Thermo Fisher Scientific Inc. (U.S.) F. Hoffmann-La Roche Ltd (Switzerland) Pacific Biosciences of California Inc. (U.S.) QIAGEN N.V. (Netherlands) Revvity Inc. (U.S.) Oxford Nanopore Technologies Plc. (U.K.) Takara Bio Inc. (Japan) Bio-Rad Laboratories Inc. (U.S.) Agilent Technologies Inc. (U.S.) 10X GENOMICS Inc. (U.S.) Promega Corporation (U.S.) Cantata Bio LLC Zymo Research Corporation (U.S.). For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
